Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology · Phase I

Oncology programs at Phase I — ClinicalTrials.gov pipeline intelligence.

Programs 1,319

Quick answer

Oncology Phase I programs: NovaPharmaNews indexes 1,319 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Pipeline programs

Page 9 of 28

  1. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Colorectal Cancer

    phase 1 mab active

    1 trial

  2. CEGF816X2102

    Novartis Pharmaceuticals

    Patients with EGFR-mutant Non Small Cell Lung Cancer

    phase 1 other active

    1 trial

  3. CEND-1

    LISATA THERAPEUTICS, INC.

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  4. CEP-11981 (kinase inhibitor)

    Teva Pharma GmbH

    Cancer

    phase 1 small molecule completed

    1 trial

  5. CEP-37440

    Teva Pharma GmbH

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  6. CEP-9722

    Teva Pharma GmbH

    Solid Tumor

    phase 1 small molecule completed

    1 trial

  7. CEP-9722

    Teva Pharma GmbH

    Solid Tumors or Mantle Cell Lymphoma

    phase 1 small molecule completed

    1 trial

  8. CEREAL-IPC 2016-010

    The George Institute

    Acute leukemia and myelodysplastic syndromes

    phase 1 other active

    1 trial

  9. CFKL480A02101

    Novartis Pharmaceuticals

    Advanced breast cancer and advanced NSCLC

    phase 1 other active

    1 trial

  10. CFT1946

    C4 Therapeutics

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  11. CFT8634

    C4 Therapeutics

    Synovial Sarcoma

    phase 1 small molecule terminated

    1 trial

  12. CFXX489A12101

    Novartis Pharmaceuticals

    Locally advanced or metastatic unresectable colorectal cancer (CRC), Locally advanced unresectable or metastatic breast cancer (BC), Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC)

    phase 1 other active

    1 trial

  13. CG-806

    Aptose Biosciences

    Chronic Lymphocytic Leukemia

    phase 1 small molecule terminated

    1 trial

  14. CG-806

    Aptose Biosciences

    Acute Myeloid Leukemia

    phase 1 small molecule terminated

    1 trial

  15. CG0070

    CG Oncology

    Muscle-Invasive Bladder Carcinoma

    phase 1 small molecule completed

    1 trial

  16. CGCJ904A12101

    Novartis Pharmaceuticals

    Locally advanced unresectable or metastatic colorectal cancer (CRC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC), Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic soft tissue sarcoma (excluding GIST and Kaposi sarcoma), Locally advanced unresectable or metastatic HR+/HER2- ductal or lobular breast cancer (BC), Locally advanced unresectable or metastatic triple negative breast cancer (TNBC)

    phase 1 other active

    1 trial

  17. CGT4255

    Cogent Biosciences

    Advanced Solid Tumor, Adult

    phase 1 small molecule active

    1 trial

  18. CHR-2797 (tosedostat)

    United Therapeutics Europe Ltd

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  19. CHS-006 (anti-TIGIT)

    Coherus Oncology

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  20. CHS-1000

    Coherus Oncology

    Advanced or Metastatic Solid Tumors

    phase 1 mab active

    1 trial

  21. CHS-114

    Coherus Oncology

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  22. CHS-114

    Coherus Oncology

    Metastatic Solid Tumor

    phase 1 small molecule active

    1 trial

  23. CHS-388

    Coherus Oncology

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

  24. CIAG933A12101

    Novartis Pharmaceuticals

    Advanced mesothelioma or other solid tumors harboring certain molecular alterations in the Hippo pathway

    phase 1 other active

    1 trial

  25. CITY

    Pari Pharma GmbH

    Cutaneous T-cell lymphomas (CTCL)

    phase 1 other active

    1 trial

  26. CKFA115A12101

    Novartis Pharmaceuticals

    Thymic Carcinoma, Nasopharyngeal Cancer, Anal Cancer, Head and Neck Squamous Cell Carcinoma, Epithelial Ovarian Cancer, Cutaneous melanoma, Mesothelioma, Non-small cell lung cancer, Esophagogastric Cancer, Triple negative breast cancer, Microsatellite Instability High Colorectal Cancer, Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  27. CLDK378A2120C

    Novartis Pharmaceuticals

    Non-small cell lung cancer

    phase 1 other active

    1 trial

  28. CLL1 and CD38 Dual-Target CAR-T Cell Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  29. CLN-049

    Cullinan Therapeutics

    Relapsed/Refractory Acute Myeloid Leukemia (AML)

    phase 1 small molecule active

    1 trial

  30. CLN-049-002

    Cullinan Therapeutics

    Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD)

    phase 1 other active

    1 trial

  31. CLN-617

    Cullinan Therapeutics

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  32. CLN-619

    Cullinan Therapeutics

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  33. CLN-619-001

    Cullinan Therapeutics

    Solid tumors, Non-Small Cell Lung Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, breast cancer, gastrointestinal cancer

    phase 1 other active

    1 trial

  34. CLR 131

    Cellectar Biosciences

    Pediatric Solid Tumor

    phase 1 small molecule active

    1 trial

  35. CLR 131

    Cellectar Biosciences

    Head and Neck Cancer

    phase 1 small molecule completed

    1 trial

  36. CMP-001

    Regeneron UK Limited

    Non Small Cell Lung Cancer

    phase 1 small molecule completed

    1 trial

  37. CMP-001

    Regeneron UK Limited

    Malignant Melanoma

    phase 1 small molecule completed

    1 trial

  38. CNTY-LTFU-01

    Century Therapeutics

    Hematological or solid tumor malignancies or autoimmune diseases

    phase 1 other active

    1 trial

  39. CO42800

    Hoffmann-La Roche

    Locally Advanced or Metastatic Solid Tumors

    phase 1 other active

    1 trial

  40. CO43805

    Hoffmann-La Roche

    Non-Hodgkin Lymphoma

    phase 1 other active

    1 trial

  41. CPDR001X2X01B

    Novartis Pharmaceuticals

    Different types of advanced cancer

    phase 1 small molecule active

    1 trial

  42. CPI-006

    Corvus Pharmaceuticals

    Non-Small Cell Lung Cancer

    phase 1 small molecule completed

    1 trial

  43. CPI-818

    Corvus Pharmaceuticals

    T-cell Lymphoma

    phase 1 small molecule active

    1 trial

  44. CPX-351

    Jazz Pharmaceuticals Ireland Limited

    Acute Myelogenous Leukemia

    phase 1 small molecule completed

    1 trial

  45. CPX-351 (Cytarabine:Daunorubicin) Liposome Injection

    Jazz Pharmaceuticals Ireland Limited

    Hematologic Neoplasms

    phase 1 small molecule completed

    1 trial

  46. CSET N°2021/3339

    The George Institute

    Neoadjuvant therapy in locally-advanced rectal cancer

    phase 1 other active

    1 trial

  47. CT-202

    Context Therapeutics

    Triple Negative Breast Cancer (TNBC)

    phase 1 small molecule active

    1 trial

  48. CT-95

    Context Therapeutics

    Mesothelin-Expressing Tumors

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many oncology Phase I programs exist?

1,319 programs match both the therapeutic area and stage filters in our published index.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.